Omacor 1000 mg Soft Capsules

  • Name:

    Omacor 1000 mg Soft Capsules

  • Company:
    info
  • Active Ingredients:

    90% Omega-3 acid ethyl esters

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 06/12/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 6/12/2019

Click on this link to Download PDF directly

Mylan IRE Healthcare Limited

Mylan IRE Healthcare Limited

Company Products

Medicine NameActive Ingredients
Medicine Name ALDARA 5% CREAM Active Ingredients Imiquimod
Medicine Name Ancotil 2.5g/250ml Solution for Infusion Active Ingredients Flucytosine
Medicine Name Brufen 400mg film-coated Tablets Active Ingredients Ibuprofen
Medicine Name Brufen 600mg film-coated tablets Active Ingredients Ibuprofen
Medicine Name Brufen Paediatric 100mg/5ml Oral Suspension Active Ingredients Ibuprofen
Medicine Name Brufen Retard 800mg prolonged release tablets Active Ingredients Ibuprofen
Medicine Name Calvidin 600mg/400IU Chewable Tablets Active Ingredients Calcium Carbonate, Colecalciferol (Vitamin D3)
Medicine Name Cibacen 10mg Film Coated Tablet Active Ingredients Benazepril Hydrochloride
Medicine Name Cibacen 5mg Film Coated Tablets Active Ingredients Benazepril Hydrochloride
Medicine Name Clozaril 100mg Tablets Active Ingredients Clozapine
Medicine Name Clozaril 25mg Tablets Active Ingredients Clozapine
Medicine Name Colifoam 10% w/w Rectal Foam Active Ingredients Hydrocortisone Acetate
Medicine Name Colofac 135mg Tablets Active Ingredients Mebeverine Hydochloride
Medicine Name Creon 10000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon 25000 Gastro-resistant Capsules Active Ingredients Pancreatin
Medicine Name Creon for Children 5000 Gastro-resistant Granules Active Ingredients Pancreatin
Medicine Name Cyklokapron 500mg Tablets Active Ingredients Tranexamic Acid
Medicine Name Dalmane 15mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Dalmane 30mg Hard Capsules Active Ingredients Flurazepam monohydrochloride
Medicine Name Desunin 4000IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name Desunin 800IU Tablets Active Ingredients Colecalciferol (Vitamin D3)
Medicine Name DIFFLAM 3% CREAM Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM ORAL RINSE Active Ingredients Benzydamine Hydrochloride
Medicine Name DIFFLAM SPRAY Active Ingredients Benzydamine Hydrochloride
Medicine Name Dona 1500mg Powder for Oral Solution Active Ingredients Glucosamine Sulfate, Sodium Chloride
1 - 0 of 97 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 6 December 2019 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 3 - dose and frequency
  • Change to section 6 - date of revision

Updated on 6 December 2019 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 2 October 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder

Updated on 2 October 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 3 April 2018 PIL

Reasons for updating

  • New PIL for new product

Updated on 3 April 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - use in children and adolescents
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - what the product looks like and pack contents

Updated on 28 March 2018 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 28 March 2018 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One capsule contains

Omega-3-acid ethyl esters 90 1000 mg
comprising 840 mg eicosapentaenoic acid (EPA) ethyl ester (460mg) and docosahexaenoic acid (DHA) ethyl ester (380mg),
including also as antioxidant 4 mg d-alpha-tocopherol (mixed with a vegetable oil e.g. soya oil)..

 

.3 Contraindications
 Hypersensitivity to the active substance, to soya or to any of the excipients listed in section 6.1.

Omacor contains soya-bean oil oil. If you are allergic to peanut or soya, do not use this medicinal product.

4.4 Special warnings and precautions for use

 Warnings

Omacor should be used with caution in patients with known sensitivity or allergy to fish.

Paediatric population
In the absence of efficacy and safety data, use of this medication in children is not recommended.

Clinical data regarding the use of Omacor in elderly patients over 70 years of age are limited.

Because of the moderate increase in bleeding time (with the high dosage, i.e. 4 capsules), patients receiving anticoagulant therapy must be monitored and the dosage of anticoagulant adjusted if necessary (see section 4.5 Interaction with other Medicinal Products and other forms of Interaction). Use of this medication does not eliminate the need for the surveillance usually required for patients of this type.
 
Make allowance for the increased bleeding time in patients at high risk of haemorrhage (because of severe trauma, surgery, etc).

In the absence of efficacy and safety data, use of this medication in children is not recommended.

During treatment with Omacor, there is a fall in thromboxane A2 production. No significant effect has been observed on the other coagulation factors. Some studies with omega-3-acids demonstrated a prolongation of bleeding time, but the bleeding time reported in these studies has not exceeded normal limits and did not produce clinically significant bleeding episodes.

Clinical data regarding the use of Omacor in elderly patients over 70 years of age are limited.

4.6 Fertility, pPregnancy and lactation
 Pregnancy
 There are no adequate data from the use of Omacor in pregnant women.
Studies in animals have not shown reproductive toxicity. The potential risk for humans is unknown and therefore Omacor should not be used during pregnancy unless clearly necessary.

Breastfeeding Lactation
There are no data on the excretion of Omacor in animal and human milk. Omacor should not be used during lactation.

Fertility
There are no adequate data on the effect of Omacor on fertility.

6. PHARMACEUTICAL PARTICULARS

6.1  List of excipients
 Capsule core :
 alpha-tocopherol

 

Updated on 3 May 2017 PIL

Reasons for updating

  • Change of distributor details

Updated on 3 May 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 1 November 2016 PIL

Reasons for updating

  • Change to section 6 - date of revision
  • Change of distributor details

Updated on 7 August 2015 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 29 April 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change of distributor details

Updated on 28 April 2015 SmPC

Reasons for updating

  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

6.1        Nature and contents of container

            White high density polyethylene (HDPE) bottle

            -     1X20 capsules

-       1x28 capsules

-       1x30 capsules

-       1x60 capsules

-       1x100 capsules

-       10x28 capsules                                          

 

            Not all pack sizes may be marketed.

Updated on 24 November 2014 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 4.9 - Overdose
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

4.2       Posology and method of administration
            
Post Myocardial Infarction

One capsule daily.

 

            Hypertriglyceridaemia

Initial treatment two capsules daily. If adequate response is not obtained, the dose may be increased to four capsules daily.

 

            The capsules may be taken with food to avoid gastrointestinal disturbances.

There is no information regarding the use of Omacor in children and adolescents, in elderly patients over 70 years of age, or in patients with hepatic impairment (see section 4.4), and only limited information regarding the use in patients with renal impairment

There is limited clinical data regarding the use of Omacor in elderly patients over 70 years of age and patients with renal impairment (see section 4.4).

There is no information regarding the use of Omacor in children and adolescents or in patients with hepatic impairment (see section 4.4).

 

 

4.4       Special warnings and precautions for use

            Warnings

 

Because of the moderate increase in bleeding time (with the high dosage, i.e. 4 capsules), patients receiving anticoagulant therapy must be monitored and the dosage of anticoagulant adjusted if necessary (see section 4.5 Interaction with other Medicinal Products and other forms of Interaction). Use of this medication does not eliminate the need for the surveillance usually required for patients of this type.

           

Make allowance for the increased bleeding time in patients at high risk of haemorrhage (because of severe trauma, surgery, etc).

 

In the absence of efficacy and safety data, use of this medication in children is not recommended.

 

During treatment with Omacor, there is a fall in thromboxane A2 production. No significant effect has been observed on the other coagulation factors. Some studies with omega-3-acids demonstrated a prolongation of bleeding time, but the bleeding time reported in these studies has not exceeded normal limits and did not produce clinically significant bleeding episodes.


Clinical data regarding the use of Omacor in elderly patients over 70 years of age are limited.

Only limited information regarding the use in patients with renal impairment is available.

 

In some patients a small but significant increase (within normal values) in ASAT and ALAT was reported, but there are no data indicating an increased risk for patients with hepatic impairment. ALAT and ASAT levels should be monitored in patients with any signs of liver damage (in particular with the high dosage, i.e. 4 capsules).

 

Omacor is not indicated in exogenous hypertriglyceridaemia (type 1 hyperchylomicronaemia). There is only limited experience in secondary endogenous hypertriglyceridaemia (especially uncontrolled diabetes).

           

There is no experience regarding hypertriglyceridaemia in combination with fibrates.

4.8        Undesirable Effects

 

The frequencies of adverse reactions are ranked according to the following : very common (> 1/10), common (> 1/100 to < 1/10); uncommon (>1/1000 to < 1/100); rare (>1/10000 to < 1/1000); very rare (< 1/10000)

Immune system disorders:

Rare: hypersensitivity

 

Metabolism and nutrition disorders:

Uncommon: hyperglycaemia, gout

 

Nervous system disorders:

Uncommon: dizziness, dysgeusia, headache

 

Vascular disorders:

Uncommon: hypotension

 

Respiratory thoracic and mediastinal disorders:

Uncommon: epistaxis

 

Gastrointestinal disorders:

Common: gastrointestinal disorders (including abdominal distension, abdominal pain, constipation, diarrhoea, dyspepsia, flatulence, eructation, gastro-oesophageal reflux disease, nausea or vomiting)

Uncommon: gastrointestinal haemorrhage

 

Hepatobiliary disorders:

Rare: liver disorders (including transaminases increased, alanine aminotransferase increased and aspartate aminotransferase increased)

 

 

Skin and subcutaneous tissue disorders:

Uncommon: rash

Rare: urticaria

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance,
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
E-mail: medsafety@hpra.ie


Updated on 20 November 2014 PIL

Reasons for updating

  • Change of inactive ingredient
  • Addition of information on reporting a side effect.

Updated on 30 August 2013 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container
  • Change to section 6.6 - Special precautions for disposal and other handling

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

- Section 2 - Administrative update
- Section 4.2 - Addition of adolescents to text
- Section 4.4 - Change to text regarding ASAT and ALAT, Addition of text regarding bleeding time
- Section 4.7 - Update of text regarding ability to drive & use machines
- Section 4.8 - Update of undesirable effects list
- Section 4.9 - Minor text revision
- Section 5.1 - Addition of pharmacotherapeutic group
- Section 5.3 - Update of text regarding pre-clinical safety data
- Section 6.1 - Update of excipient list
- Section 6.5 - Addition of description of bottle
- Section 6.6 - Addition of waste disposal information

Updated on 23 August 2013 PIL

Reasons for updating

  • Change to instructions about overdose
  • Change to side-effects
  • Change of distributor details

Updated on 10 June 2010 PIL

Reasons for updating

  • Change of distributor details

Updated on 5 August 2009 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 1 February 2008 SmPC

Reasons for updating

  • Change to MA holder contact details

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Section 7. Marketing Authorisation Holder; Change of company name and address

Updated on 3 April 2007 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

Previous

1.         NAME OF THE MEDICINAL PRODUCT

Omacor, capsule, soft                 

 

9.         DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

22 July 2001

 

10.        DATE OF REVISION OF THE TEXT

January 2006

 

AMENDED

 

1.                   NAME OF THE MEDICINAL PRODUCT

Omacor 1000 mg Soft Capsules

 

7.                   DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION

8 August 2003/22 July 2006

 

8.                   DATE OF REVISON OF THE TEXT

January 2007

 

 

Updated on 26 February 2007 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 28 June 2006 PIL

Reasons for updating

  • Improved electronic presentation
  • Change to warnings or special precautions for use
  • Change to drug interactions

Updated on 11 April 2006 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients
  • Change to section 6.5 - Nature and contents of container
  • Change to section 7 - Marketing authorisation holder

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 1 August 2005 PIL

Reasons for updating

  • Change of contraindications
  • Change to warnings or special precautions for use

Updated on 15 February 2005 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 15 February 2005 PIL

Reasons for updating

  • New PIL for new product

Updated on 29 August 2003 SmPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)